UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
April
20, 2009
(Date of
Earliest Event Reported)
Advaxis,
Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
00028489
|
02-0563870
|
|
(State or other
jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
Technology
Centre of New Jersey
675
Rt. 1, Suite B113
North
Brunswick, N.J. 08902
(Address
of principal executive offices)
(732) 545-1590 (Registrant’s
telephone number, including area code)
|
(Former name or former address,
if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events
On
April 20, 2009, Advaxis, Inc. issued a press release regarding its drug
licensing discussions for its flagship vaccine construct, ADXS11-001 and the
postponement of its annual shareholders’ meeting until further
notice.
A
copy of the press release is attached as Exhibit 99.1 to this Current Report and
is incorporated herein by this reference.
Item
9.01 Financial Statements and
Exhibits
99.1 Advaxis,
Inc. press release, dated April 20, 2009
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated:
April 20, 2009
|
Advaxis,
Inc.
|
||
|
By:
|
/s/
Thomas A. Moore
|
|
|
Name:
|
Thomas
A. Moore
|
|
|
Title:
|
Chief
Executive Officer
|
|
 |
EXHIBIT
99.1
|
ADVAXIS IN DRUG LICENSING
DISCUSSIONS
FOR ITS FLAGSHIP VACCINE CONSTRUCT,
ADXS11-001
__________________________________
ANNUAL GENERAL MEETING
RESCHEDULED
UNTIL COMPLETION OF LICENSING
DISCUSSIONS
North
Brunswick, NJ – April 17, 2009 –
Advaxis,
Inc.
(OTCBB: ADXS) is in drug
licensing discussions for its flagship vaccine construct, ADXS11-001(formerly
named Lovaxin-C), in non-US markets.
Due to the potential materiality of the
aforementioned event, Advaxis ' annual general meeting, which was scheduled for
Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing
contract is completed.
ADXS11-001 is a therapeutic vaccine,
like Dendreon’s Provenge, that treats active cancer, but much
lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic
vaccines, ADXS 11-001 treats women who have already developed cervical cancer as
a result of human papilloma virus (HPV) infection; the most prevalent sexually
transmitted disease in the US today. Advaxis has already filed an IND for a Phase II trial in HPV caused
cervical intraepithelial neoplasia (CIN), which is
pre-cancerous.
About the ADXS11-001
Immunotherapy
Advaxis’ technology platform uses
modified Listeria
monocytogenes to deliver a
tumor-specific antigen fusion protein. Pre-clinically, bioengineered
attenuated Listeria that secrete Advaxis’ proprietary
fusion protein have the ability to generate a robust immune response, break
immune tolerance to cancer and produce an unusually strong and effective
multi-level therapeutic immune response to existing cancer and other
diseases.
Advaxis’ Listeria-based technology is based on over a
decade worth of work by Dr. Yvonne Paterson in her laboratory at the
University of Pennsylvania. The Company’s proprietary antigen
fusion protein technology stimulates innate immunity i.e., both arms of the
adaptive cellular immune system, suppresses regulatory T-cells that inhibit many
vaccines in the function of activated tumor-killing cells in addition to other
anti-tumor effects.
For further information on ADXS11-001,
please visit: www.advaxis.com/lc.htm.
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary
Listeria
monocytogenes (Lm) cancer
vaccines based on technology developed by Dr. Yvonne Paterson, professor of
microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific
advisory board. Advaxis is developing attenuated live Lm vaccines that deliver
engineered tumor antigens, which stimulate multiple simultaneous immunological
mechanisms to fight cancer.
For further information on the Company,
please visit: www.advaxis.com.
Forward-Looking
Statements
Certain statements contained in this
press release are forward-looking statements that involve risks and
uncertainties. The statements contained herein that are not purely historical
are forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements deal with the Company’s
current plans, intentions, beliefs and expectations and statements of future
economic performance. Forward-looking statements involve known and unknown risks
and uncertainties that may cause the Company's actual results in future periods
to differ materially from what is currently anticipated. Factors that could
cause or contribute to such differences include those discussed from time to
time in reports filed by the Company with the Securities and Exchange
Commission. The Company cannot guarantee its future results, levels of activity,
performance or achievements.
For Further
Information:
Conrad Mir
Director, Business
Development
Advaxis, Inc.
732.545.1590
(Office)
732.545.1084 (FAX)
conradmir@advaxis.com
www.advaxis.com